Preclinical evaluation of intravenously administered 111in- and 90y-labeled b72.3 immunoconjugate (GYK-DTPA) in beagle dogs
- 1 July 1993
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 20 (5) , 559-570
- https://doi.org/10.1016/0969-8051(93)90024-o
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Selection of reagents for human radioimmunotherapyInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Clinical Pharmacology, Metabolism, and Tissue Distribution of 90Y-Labeled Monoclonal Antibody B72.3 After Intraperitoneal AdministrationJNCI Journal of the National Cancer Institute, 1991
- Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01.Journal of Clinical Oncology, 1991
- Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer.Journal of Clinical Oncology, 1990
- Polyclonal 90yttrium labeled antiferritin for refractory Hodgkin's diseaseInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Effects of hepatic arterial yttrium 90 glass microspheres in dogsCancer, 1988
- Treatment of B cell malignancies with131I LYM-1 monoclonal antibodiesInternational Journal of Cancer, 1988
- Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study.Journal of Clinical Oncology, 1987
- Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease.Journal of Clinical Oncology, 1985
- Alternatives to donor matching for control of graft-versus-host diseaseImmunogenetics, 1982